US FTC orders Illumina to divest cancer detection test maker Grail
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Illumina (ILMN) to appeal FTC decision ordering the unwinding of GRAIL deal
April 3, 2023 12:03 PM EDTIllumina (NASDAQ: ILMN) will appeal the Federal Trade Commission's (FTC) decision to order the unwinding of Illumina's $7.1 billion acquisition of GRAIL, the company announced.
The FTC issued an Opinion and Order on Monday, requiring the DNA sequencing provider to divest GRAIL, stating that the deal would stifle competition and innovation in the U.S. market for life-saving cancer tests.
The decision by the FTC reverses an administrative... More
